New research evaluates clinical trials investigating post-acute COVID-19 syndrome treatment

In a recent article published in Clinical Microbiology and Infection, researchers reviewed all registered trials currently investigating potential treatment options for post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS).

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

COVID-19 therapeutics: Challenges and directions for the future

NIA-Funded Active Alzheimer's and Related Dementias Clinical Trials and Studies

Long COVID NIH COVID-19 Research

COVID-19: Drug Targets and Potential Treatments

CDC Museum COVID-19 Timeline, David J. Sencer CDC Museum

Paxlovid May Reduce Risk of Long Covid in Eligible Patients, Study Finds - The New York Times

Trauma Care, Free Full-Text

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Penn Study Finds Serotonin Reduction Causes Long COVID Symptoms

Frontiers Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative

What We Know about Long COVID—and What We Don't, The Brink

Rehabilitation needs following COVID-19: Five-month post-discharge clinical follow-up of individuals with concerning self-reported symptoms - eClinicalMedicine

Post-acute COVID-19 syndrome

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial - The Lancet Respiratory Medicine